ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC
June 25th 2024
Panel experts analyze findings from the phase 3 ADRIATIC trial, examining overall and progression-free survival data, exploring the interaction between durvalumab and concurrent chemoradiotherapy within the tumor microenvironment, and evaluating the impact of time intervals from the completion of concurrent chemoradiotherapy to the initiation of consolidation therapy with a PD-L1 inhibitor.